May 22, 2025 4:43pm

Sector equity year-to-date performance remains bottom-based

The wall of worry emerges as valuations are inflated then deflated while economic-related gradations are heightened, on and on

Expect volatility to be more the norm versus exception

Always be vigilant concerning your portfolio … why you need RMi!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Thursday, RegMed Investors’ (RMi) pre-open: Volatility governs … https://www.regmedinvestors.com/articles/13929

Wednesday night’s RegMed Investors (RMi) Closing Bell: Market and sector whipsawed by treasury yields … https://www.regmedinvestors.com/articles/13928

 

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed DOWN -0.00 points or -1.35%, the S&P closed DOWN -2.60 points or -0.04% while the Nasdaq closed UP +53.09 points or +0.28%

  • Indexes were mixed and barely with the Nasdaq positive as House members approved the budget bill that includes lower taxes and additional military spending. The bill — which now goes to the Senate

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Short term, the tax bill is good for the economy, sure to boost GDP growth in 2026; reducing taxes, it increases spending, especially on defense, and stimulative to the economy.”

Thursday’s advance/decline line opened with a negative 8 incliner, 25 decline and 2 flats ending with a barely positive close of 19 incliners, 14 decliners and 2 flats     

Metrics:  Wednesday, the IBB was down -0.27%, the XBI was down -0.06% while the VIX was down -0.62 points or -2.97% at 20.25

 

Q2/25 – May – 7 negative and 9 positive closes

  • April – 11 positive and 10 negative closes

Q1/25

  • March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Thursdays Closing UP (10 of 19) 

  • Moderna (MRNA +$0.92 after Wednesday’s -$2.19 after Tuesday’s +$1.53),
  • CRISPR Therapeutics (CRSP +$0.54 after Wednesday’s -$2.26 after Tuesday’s -$0.09),
  • Vericel (VCEL +$0.31 after Wednesday’s -$2.45),
  • Intellia Therapeutics (NTLA +$0.26 after Wednesday’s -$0.47 after Tuesday’s +$0.56),
  • Regenxbio (RGNX +$0.22),
  • Solid Biosciences (SLDB +$0.19),
  • Verve Therapeutics (VERV +$0.15),
  • Agenus (AGEN +$0.13),
  • Editas Medicine (EDIT +$0.12),
  • Ultragenyx Pharmaceuticals (RARE +$0.10 after Wednesday’s -$1.94 after Tuesday’s +$0.58),

Flat (2)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Monday’s -$0.14 after Friday’s $0.00
  • Homology Medicine (FIXX)

Thursday’s Closing DOWN (10 of 30): 

  • Alnylam Pharmaceuticals (ALNY -$3.58 after Wednesday’s +$0.90),
  • Blueprint Medicine (BPMC -$1.17 after Wednesday’s -$1.49 after Tuesday’s -$0.48),
  • AxoGen (AXGN -$0.46),
  • Mesoblast (MESO -$0.43),
  • uniQure NV (QURE -$0.27 after Wednesday’s +$0.19),
  • Ionis Pharmaceuticals (IONS -$0.24 after Wednesday’s -$0.97 after Tuesday’s +$0.47),
  • Sage Therapeutics (SAGE -$0.19),
  • MiMedx (MDXG -$0.18),
  • Voyager Therapeutics (VYGR -$0.16),
  • Brainstorm Cell Therapeutics (BCLI -$0.07),

 

The BOTTOM LINE: Cell and gene therapy sector equities made a little progress on Thursday.

Algos … Kiss my “tuchas” …  I keep warning of … induced …degrades, retrogrades and upgrades of share pricing.

Thursday's positive close unfollows Wednesday’ negative finish, Tuesday’s following Monday’s positive …

  • A poor auction for 20-year Treasury debt helped fuel the spike in yields and the stock drops on Wednesday which sent stocks tumbling.
  • After indexes slid on Tuesday, pulling back from their recent rally amid growing warnings that investor relief over a cooling in trade tensions and in US inflation may be misplaced.

 

May ‘25: understand the “flow” …

  • 5/22 – Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 5/21 – Wednesday closed negative with 3 positive, 30 negative and 2 flats
  • 5/20 – Tuesday closed positive with 23 positive, 9 negative and 3 flats
  • 5/19 – Monday closed positive with 23 positive, 12 negative and 1 flat
  • 5/16 - Friday closed positive with 29 positive, 3 negative and 3 flats
  • 5/15 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/14 – Wednesday closed negative with 8 positive, 25 negative and 2 flats
  • 5/13 – Tuesday closed negative with 6 positive, 28 negative and 1 flat
  • 5/12 - Monday positive with 39 positive, 3 negative and 2 flats
  • 5/9 - Friday closed negative with 10 positive, 23 negative and 2 flats
  • 5/8 – Thursday closed positive with 25 positive, 8 negative and 2 flats
  • 5/7 - Wednesday closed positive with 16 positive, 15 negative and 4 flats
  • 5/6 – Tuesday closed negative with 2 positive, 31 negative and 2 flats
  • 5/5 - Monday closed negative with 9 positive, 23 negative and 3 flats
  • 5/2 – Friday closed positive with 24 positive, 8 negative and 3 flats
  • 5/1 - Thursday closed negative with 14 positive, 19 negative and 2 flats

 

I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.” <me>

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Moderna (MRNA), CRISPR Therapeutics CRSP) and Vericel (VCEL)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Sangamo Therapeutics (SGMO)
  • Tuesday: Blueprint Medicine (BPMC), Moderna (MRNA) and Ultragenyx Pharmaceuticals (RARE)
  • Monday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Moderna (MRNA)

The worst three (3) in the session: 

  • Thursday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and AxoGen (AXGN)
  • Wednesday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and Moderna (MRNA)
  • Tuesday: AxoGen (AXGN), Alnylam Pharmaceuticals (ALNY) and Prime Medicine (PRME)
  • Monday: BioLife Solutions (BLFS), Blueprint Medicine (BPMC) and Verve therapeutics (VERV)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.